



# SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 3

Page 1 / 15

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
**Product Code(s)** PZ03125  
**Trade Name:** Naloxone Hydrochloride Injection  
**Chemical Family:** Mixture

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous.

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**

Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**

Not applicable

### 2.2. Label elements

**Signal word** Not classified

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 2 / 15  
Version 3

## Hazard statements

Not classified in accordance with international standards for workplace safety.

## 2.3. Other hazards

### Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Chemical name	EU - REACH (1907/2006) - Article 59(1) - Candidate List of Substances of Very High Concern (SVHC) for Authorisation	EU - REACH (1907/2006) - Endocrine Disruptor Assessment List of Substances
Propylparaben	-	Endocrine disrupting properties

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Methyl-p-hydroxybenzoate (CAS #: 99-76-3)	< 1		202-785-7	Not classified	Not classified	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7 (017-002-00-2) (017-002-01-X)	Press. Gas Skin Corr. 1A (H314) Acute Tox. 3 (H331)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10%	No data available	No data available
Naloxone hydrochloride (CAS #: 357-08-4)	0.04		206-611-0	Not classified	Not classified	No data available	1
Propylparaben (CAS #: 94-13-3)	< 1		202-307-7	Not classified	Not classified	No data available	No data available

#### NonHazardous

Chemical name	Weight-%	REACH	EC No (EU	Classification	Specific	M-Factor	M-Factor
---------------	----------	-------	-----------	----------------	----------	----------	----------

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 3 / 15  
Version 3

		registration number	Index No)	according to Regulation (EC) No. 1272/2008 [CLP]	concentration limit (SCL)		(long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

## Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022
Naloxone hydrochloride 357-08-4	> 1000	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

+ Substance with a Union workplace exposure limit

\* Proprietary

\*\* to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	If symptoms persist, call a physician.
Skin contact	Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

**Most important symptoms and** For information on potential signs and symptoms of exposure, See Section 2 - Hazards

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 4 / 15  
Version 3

**effects** Identification and/or Section 11 - Toxicological Information.

## **4.3. Indication of any immediate medical attention and special treatment needed**

**Note to physicians** None.

## **Section 5: FIRE-FIGHTING MEASURES**

### **5.1. Extinguishing media**

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

### **5.2. Special hazards arising from the substance or mixture**

**Specific hazards arising from the chemical** Not applicable.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire.

#### **Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### **5.3. Advice for firefighters**

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## **Section 6: ACCIDENTAL RELEASE MEASURES**

### **6.1. Personal precautions, protective equipment and emergency procedures**

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### **6.2. Environmental precautions**

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### **6.3. Methods and material for containment and cleaning up**

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### **6.4. Reference to other sections**

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

### **7.1. Precautions for safe handling**

**Advice on safe handling** Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 5 / 15  
Version 3

thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

## 7.2. Conditions for safe storage, including any incompatibilities

### Storage Conditions

Store as directed by product packaging.

## 7.3. Specific end use(s)

### Specific use(s)

Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Naloxone hydrochloride

Pfizer OEL TWA-8 Hr: 200 µg/m<sup>3</sup>

#### Methyl-p-hydroxybenzoate

Russia

MAC: 4 mg/m<sup>3</sup>

#### SODIUM CHLORIDE

Latvia

TWA: 5 mg/m<sup>3</sup>;

Russia

MAC: 5 mg/m<sup>3</sup>

#### + Hydrochloric Acid

ACGIH OEL (Ceiling)

2 ppm

ACGIH TLV

Ceiling: 2 ppm

Austria

TWA-TMW: 5 ppm;

TWA-TMW: 8 mg/m<sup>3</sup>;

STEL-KZGW: 10 ppm (8 X 5 min);

STEL-KZGW: 15 mg/m<sup>3</sup> (8 X 5 min);

Bulgaria

TWA: 5 ppm;

TWA: 8.0 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15.0 mg/m<sup>3</sup>;

Czech Republic

8 mg/m<sup>3</sup>

Ceiling: 15 mg/m<sup>3</sup>

Denmark

STEL: 5 ppm;

STEL: 8 mg/m<sup>3</sup>;

Estonia

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

European Union

TWA: 5 ppm;

TWA: 8 mg/m<sup>3</sup>;

STEL: 10 ppm;

STEL: 15 mg/m<sup>3</sup>;

Finland

STEL: 5 ppm;

STEL: 7.6 mg/m<sup>3</sup>;

Germany DFG

TWA-MAK: 2 ppm; I(2);

TWA-MAK: 3.0 mg/m<sup>3</sup>; I(2);

Peak: 4 ppm;

Peak: 6 mg/m<sup>3</sup>;

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 6 / 15  
Version 3

Germany TRGS	TWA-AGW; 2 ppm (exposure factor 2); TWA-AGW; 3 mg/m <sup>3</sup> (exposure factor 2);
Hungary	TWA-AK: 8 mg/m <sup>3</sup> ; TWA-AK: 5 ppm; STEL-CK: 165 mg/m <sup>3</sup> ; STEL-CK: 10 ppm;
Ireland	TWA: 8 mg/m <sup>3</sup> ; TWA: 5 ppm; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Italy MDLPS	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Ceiling Limit Value	2 ppm 3.0 mg/m <sup>3</sup>
Latvia	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Netherlands	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Poland	TWA-NDS: 5 mg/m <sup>3</sup> ; STEL-NDSch: 10 mg/m <sup>3</sup> ;
Romania	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Russia	MAC: 5 mg/m <sup>3</sup>
Slovakia	TWA: 5 ppm; TWA: 8.0 mg/m <sup>3</sup> ; Ceiling: 15 mg/m <sup>3</sup> ;
Spain	TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m <sup>3</sup> ; STEL (VLA-EC): 10 ppm; STEL (VLA-EC): 15 mg/m <sup>3</sup> ;
Switzerland	TWA-MAK: 2 ppm; TWA-MAK: 3 mg/m <sup>3</sup> ; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m <sup>3</sup> ;
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m <sup>3</sup>
OSHA PEL	Ceiling: 5 ppm Ceiling: 7 mg/m <sup>3</sup> (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m <sup>3</sup>
United Kingdom	TWA: 1 ppm; gas and aerosol mist TWA: 2 mg/m <sup>3</sup> ; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m <sup>3</sup> ; gas and aerosol mist
<b>Propylparaben</b>	
Russia	MAC: 10 mg/m <sup>3</sup>

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so,

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 7 / 15  
Version 3

but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### Thermal hazards

No information available.

### Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

#### Appearance

Solution

#### Physical state

Liquid

#### Color

Colorless

#### Odor

No information available.

#### Odor threshold

No information available

#### Property

#### Values

#### Melting point / freezing point

No data available

#### Boiling point or initial boiling point and boiling range

No data available

#### Flammability (solid, gas)

No data available

#### Lower and upper explosion limit/flammability limit

#### Lower explosion limit

No data available

#### Upper explosion limit

No data available

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 8 / 15  
Version 3

Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	3.0-6.5
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

## Partition Coefficient: (Method, pH, Endpoint, Value)

### Naloxone hydrochloride

Measured 5 Log P -1.16

Measured 7 Log P 0.628

Measured 9 Log P 1.41

## 9.2. Other information

Molecular formula

Mixture

Molecular weight

Mixture

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under normal conditions.

#### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

### 10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

### 10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

Hazardous decomposition products Thermal decomposition products may include carbon monoxide, carbon dioxide, oxides of nitrogen and hydrogen chloride.



# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 9 / 15  
Version 3

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

<b>General Information:</b>	The information included in this section describes the potential hazards of the individual ingredients
<b>Known Clinical Effects:</b>	The most common adverse effects seen during clinical use of this drug include headache, sweating, nausea, decrease in blood pressure (hypotension), increase in blood pressure (hypertension), shortness of breath (dyspnea), increased heart rate (tachycardia), irritability, anxiety, inability to concentrate, lack of appetite.
<b>Acute toxicity</b>	Based on available data, the classification criteria are not met.
<b>Serious eye damage/eye irritation</b>	Based on available data, the classification criteria are not met.
<b>Skin corrosion/irritation</b>	Based on available data, the classification criteria are not met.
<b>Respiratory or skin sensitization</b>	Based on available data, the classification criteria are not met.
<b>STOT - single exposure</b>	Based on available data, the classification criteria are not met.
<b>STOT - repeated exposure</b>	Based on available data, the classification criteria are not met.
<b>Reproductive toxicity</b>	Based on available data, the classification criteria are not met.
<b>Germ cell mutagenicity</b>	Based on available data, the classification criteria are not met.
<b>Carcinogenicity</b>	Based on available data, the classification criteria are not met.
<b>Aspiration hazard</b>	Based on available data, the classification criteria are not met.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Methyl-p-hydroxybenzoate

Mouse Oral LD50 > 8 g/kg  
Rat Oral LD 50 2100 mg/kg

##### SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>  
Rat Oral LD 50 3 g/kg  
Mouse Oral LD 50 4 g/kg  
Rabbit Dermal LD 50 > 10 g/kg

##### Naloxone hydrochloride

Rat Oral LD50 > 1000 mg/kg  
Mouse Oral LD50 > 1000 mg/kg  
Rat Intravenous LD50 107 mg/kg  
Mouse Intravenous LD50 90 mg/kg

##### Propylparaben

Mouse Oral LD 50 6332 mg/kg  
Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
SODIUM CHLORIDE	= 3550 mg/kg ( Rat )	> 10000 mg/kg ( Rabbit )	> 42 mg/L ( Rat ) 1 h
+ Hydrochloric Acid	238 - 277 mg/kg ( Rat )	> 5010 mg/kg ( Rabbit )	= 1.68 mg/L ( Rat ) 1 h
Naloxone hydrochloride	> 1 g/kg ( Rat )	-	-

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Methyl-p-hydroxybenzoate

Skin irritation Rabbit Non-irritating

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 10 / 15  
Version 3

Eye irritation Rabbit Slight  
Skin Sensitization Guinea Pig Negative

## **+ Hydrochloric Acid**

Skin irritation Severe  
Eye irritation Severe

## **SODIUM CHLORIDE**

Skin irritation Rabbit Mild  
Eye irritation Rabbit Mild

## **Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

### **Methyl-p-hydroxybenzoate**

28 Day(s) Rat Oral 250 mg/kg/day NOEL Gastrointestinal System, Spleen, Thymus

### **Naloxone hydrochloride**

3 Month(s) Rat Oral 2.13 mg/kg/day NOEL None identified  
3 Month(s) Dog Oral 0.68 mg/kg/day NOEL None identified  
9 Month(s) Dog Oral 75 mg/kg/day NOEL Brain, Pituitary, Thymus, Central Nervous System  
30 Day(s) Monkey Subcutaneous 60 mg/kg/day LOEL Central Nervous System  
2 Year(s) Rat Oral 4 mg/kg/day LOEL Gastrointestinal system, Female reproductive system

### **Propylparaben**

3 Week(s) Rat Oral 27.1 g/kg LOEL Endocrine system  
4 Week(s) Rat Oral 347.2 mg/kg LOEL Male reproductive system

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Methyl-p-hydroxybenzoate**

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

### **Naloxone hydrochloride**

Embryo / Fetal Development Rat No route specified 8 times human dose NOEL Not teratogenic  
Embryo / Fetal Development Mouse No route specified 4 times human dose NOEL Not Teratogenic  
Fertility and Embryonic Development Rat Oral 200 mg/kg/day NOEL Paternal toxicity  
Fertility and Embryonic Development Rat Oral 200 mg/kg/day NOEL Fetotoxicity  
Embryo / Fetal Development Rat Oral 800 mg/kg/day NOEL No effects at maximum dose  
Embryo / Fetal Development Rabbit Oral 400 mg/kg/day NOEL No effects at maximum dose  
Peri-/Postnatal Development Rat Oral 200 mg/kg/day NOEL Fetotoxicity

## **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

### **Methyl-p-hydroxybenzoate**

*In Vivo* Dominant Lethal Assay Rat Negative

### **+ Hydrochloric Acid**

Bacterial Mutagenicity (Ames) *Salmonella* Negative

*In Vivo* Micronucleus Rat Negative

### **Naloxone hydrochloride**

Bacterial Mutagenicity (Ames) Positive

*In Vitro* Chromosome Aberration Human Lymphocytes Positive

Mammalian Cell Mutagenicity HGPRT Hamster Negative

*In Vivo* Chromosome Aberration Rat Bone Marrow Negative

*In Vivo* Micronucleus Mouse Bone Marrow Negative

## **Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Naloxone hydrochloride**

26 Week(s) Mouse Oral 200 mg/kg/day NOEL Not carcinogenic

52 Week(s) Rat Oral 25 mg/kg/day LOEL Not carcinogenic

2 Year(s) Rat Oral 100 mg/kg/day NOEL Not carcinogenic

### **Carcinogenicity**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### **+ Hydrochloric Acid**

IARC

Group 3

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 11 / 15  
Version 3

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 11.2.2. Other information

**Other adverse effects** No information available.

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### Methyl-p-hydroxybenzoate

*Oryzias latipes* (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/L

*Daphnia magna* (Water Flea) ISO EC50 48 hours 11.2 mg/L

##### Naloxone hydrochloride

*Pseudokirchneriella subcapitata* (Green Alga) OECD ErC50 72 hours > 36 mg/L

*Pseudokirchneriella subcapitata* (Green Alga) OECD NOEC 72 hours 5.5 mg/L

#### Bacterial Inhibition: (Inoculum, Method, End Point, Result)

##### Naloxone hydrochloride

Activated sludge OECD EC50 > 1000 mg/L

#### Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

##### Naloxone hydrochloride

*Daphnia magna* (Water Flea) OECD 21 Day(s) NOEC 0.96 mg/L Reproduction

*Daphnia magna* (Water Flea) OECD 21 Day(s) EC50 > 0.96 mg/L Reproduction

*Pimephales promelas* (Fathead Minnow) OECD 34 Day(s) NOEC 0.061 mg/L Growth

### 12.2. Persistence and degradability

#### **Persistence and degradability**

#### Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

##### Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89 % After 28 Day(s) Ready

##### Naloxone hydrochloride

OECD Water - Sediment (various) Mineralization 10.2 & 6.3 % in 103 Day(s) N/A

OECD Water - Sediment (various) Total System DT50 28 & 103 Day(s) N/A

### 12.3. Bioaccumulative potential

#### **Bioaccumulation**

#### Partition Coefficient: (Method, pH, Endpoint, Value)

##### Naloxone hydrochloride

Measured 5 Log P -1.16

Measured 7 Log P 0.628

Measured 9 Log P 1.41

### 12.4. Mobility in soil

#### **Mobility in soil**

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 12 / 15  
Version 3

## Sorption:

### Naloxone hydrochloride (357-08-4)

Method	Inoculum	End Point	Result
OECD	Soil (various)	Kd (Geometric mean)	12
OECD	Soil (various)	Koc (Geometric mean)	3
OECD	Sediment (various)	Kd (Geometric mean)	53
OECD	Sediment (various)	Koc (Geometric mean)	2
OECD	Activated sludge	Kd	7.76
OECD	Activated sludge	Koc	1.34

## 12.5. Results of PBT and vPvB assessment

### PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Methyl-p-hydroxybenzoate	Not PBT/vPvB
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Propylparaben	Not PBT/vPvB

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

**UN number:** Not applicable  
**UN proper shipping name:** Not applicable  
**Transport hazard class(es):** Not applicable  
**Packing group:** Not applicable  
**Environmental Hazard(s):** Not applicable

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 13 / 15  
Version 3

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-791-2
<b>AICS</b>	Present

Methyl-p-hydroxybenzoate

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	202-785-7
<b>AICS</b>	Present

SODIUM CHLORIDE

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-598-3
<b>AICS</b>	Present

+ Hydrochloric Acid

<b>CERCLA/SARA Section 313 de minimus %</b>	1.0 %
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-595-7
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6

Naloxone hydrochloride

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	206-611-0

Propylparaben

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	202-307-7
<b>AICS</b>	Present

### National regulations

#### France

#### Occupational Illnesses (R-463-3, France)

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

#### Germany

#### Chemical Prohibition Ordinance (ChemVerbotsV)

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 14 / 15  
Version 3

Not applicable

TRGS 905

Not applicable

## Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

### Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
+ Hydrochloric Acid 7647-01-0	75	-

## Persistent Organic Pollutants

Not applicable

## Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid 7647-01-0	25	250

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

## EU - Plant Protection Products (1107/2009/EC)

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent

## Biocidal Products Regulation (EU) No 528/2012 (BPR)

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene
+ Hydrochloric Acid 7647-01-0	Product-type 2: Disinfectants and algicides not intended for direct application to humans or animals

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

# SAFETY DATA SHEET

Product Name Naloxone Hydrochloride Injection, USP (Hospira Inc.)  
Revision date 16-Jun-2025

Page 15 / 15  
Version 3

**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing Chemicals Inventory  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances  
**NZIoC** - New Zealand Inventory of Chemicals  
**TCSI** - Taiwan Chemical Substance Inventory

## **15.2. Chemical safety assessment**

**Chemical Safety Report** No information available

## **Section 16: OTHER INFORMATION**

### **Key or legend to abbreviations and acronyms used in the safety data sheet**

#### **Full text of any hazard and/or precautionary statements referred to under Sections 2-15**

H314 - Causes severe skin burns and eye damage. H335 - May cause respiratory irritation. H410 - Very toxic to aquatic life with long lasting effects. H411 - Toxic to aquatic life with long lasting effects. H401 - Toxic to aquatic life. H412 - Harmful to aquatic life with long lasting effects.

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

**Reason for revision** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

**Revision date** 16-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**